Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NYCE T Cells in Advanced Cancers
NCT03399448Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Sep 2018
- Primary completion
- Feb 2020
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NYCE T cells in multiple myeloma (MM), melanoma, synovial sarcoma (SS) and 1 more (3 arms), sponsored by University of Pennsylvania. Primary endpoints: Frequency and severity of adverse events at 5 years and Manufacturing Feasibility of NYCE T Cells at 5 years. Started Sep 2018; status: terminated.
02
Drugs
NYCE T cells
03
Conditions
multiple myeloma (MM)melanomasynovial sarcoma (SS)myxoid round cell liposarcoma (MRCLPS)
Beyond the preview
Go deeper on NCT03399448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399448.